NCT02799862View on ClinicalTrials.gov

Nab-Paclitaxel in Combination With Carboplatin as First-line Therapy in Patients With NSCLC

CompletedOBSERVATIONAL
Enrollment

408

Participants

Timeline

Start Date

August 29, 2016

Primary Completion Date

December 7, 2019

Study Completion Date

June 6, 2021

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

Nab-Paclitaxel

Nab-Paclitaxel will be administered in accordance with the SmPC of Nab-Paclitaxel.

DRUG

Carboplatin

Carboplatin will be administered as combination partner of Nab-Paclitaxel in accordance with SmPC of Nab-Paclitaxel.

Trial Locations (1)

79106

iOMEDICO, Freiburg im Breisgau

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

iOMEDICO AG

INDUSTRY

NCT02799862 - Nab-Paclitaxel in Combination With Carboplatin as First-line Therapy in Patients With NSCLC | Biotech Hunter | Biotech Hunter